• Cancer is complex disease, which involve alternation of multiple genetic and epigenetic factors and pathways in normal cells for them to become cancerous. Because of its complex nature and the ability of cancer cells to evolve rapidly undertreatment, cancer treatment with durable outcome is a challenging problem. Therefore, in-depth molecular understanding of cancer initiation and progression is necessary for developing effective therapies. In-order to identify and characterize critical cancer vulnerability genes and their downstream network we use genomic and targeted approaches. Our research program spans several cancer types including melanoma, hepatocellular carcinoma, breast cancer, ovarian cancer and pancreatic cancer. Our long-term goal is to not only identify new molecules and signaling pathways that regulate the disease but also develop more effective and durable cancer therapies.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer 2023
    2022 UBE2T promotes breast cancer tumor growth by suppressing DNA replication stressNAR Cancer.  4. 2022
    2022 Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth.iScience.  25:104752. 2022
    2022 Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinomaFrontiers in Oncology.  12. 2022
    2022 Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma CellsFrontiers in Oncology.  12. 2022
    2022 Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosisiScience.  25. 2022
    2022 Transcriptional determinants of cancer immunotherapy response and resistanceTrends in Cancer.  8:404-415. 2022
    2022 Epigenetic regulation and targeting of ECM for cancer therapy 2022
    2021 Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapiesCancer Research.  81:5589-5595. 2021
    2021 The brd9/7 inhibitor tp-472 blocks melanoma tumor growth by suppressing ecm-mediated oncogenic signaling and inducing apoptosisCancers.  13. 2021
    2021 EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner 2021
    2021 Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosisOncogenesis.  10. 2021
    2021 PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1Oncogene.  40:2448-2462. 2021
    2020 Transcriptional regulators and alterations that drive melanoma initiation and progressionOncogene.  39:7093-7105. 2020
    2020 LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1Oncogenesis.  9. 2020
    2020 KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity 2020
    2020 Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1ROncogenesis.  9. 2020
    2020 Measurement of natural killer cell-mediated cytotoxicity and migration in the context of hepatic tumor cellsJournal of Visualized Experiments.  2020. 2020
    2020 Identification of the mutational landscape of gynecological malignanciesJournal of Cancer.  11:4870-4883. 2020
    2019 Dissecting the role of RNA modification regulatory proteins in melanomaOncotarget.  10:3745-3759. 2019
    2019 Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway 2019
    2018 Interleukin 8 is a biomarker of telomerase inhibition in cancer cellsBMC Cancer.  18. 2018
    2018 Zinc finger protein 598 inhibits cell survival by promoting UV-induced apoptosisOncotarget.  9:5906-5918. 2018
    2017 Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progressionOncogene.  36:4014-4024. 2017
    2017 Transcriptional analysis-based integrative genomics approach to identify tumor-promoting metabolic genesMethods in Molecular Biology.  1507:269-276. 2017
    2016 Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growtheLife.  5. 2016
    2016 Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer CellsCell Reports.  16:457-471. 2016
    2016 70S-scanning initiation is a novel and frequent initiation mode of ribosomal translation in bacteria. 2016
    2015 LKB1 preserves genome integrity by stimulating BRCA1 expressionNucleic Acids Research.  43:259-271. 2015
    2014 A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signalingCancer Discovery.  4:1169-1181. 2014
    2014 PTEN functions as a melanoma tumor suppressor by promoting host immune responseOncogene.  33:4632-4642. 2014
    2014 Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A 2014
    2013 Induction of cellular senescence by oncogenic RASMethods in Molecular Biology.  1048:127-133. 2013
    2010 Advances in genome-wide DNA methylation analysis 2010
    2008 Structural determinant of human La protein critical for internal initiation of translation of hepatitis C virus RNA.Journal of Virology.  82:11927-11938. 2008
    2006 Analysis of mutations within the 5' untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India.Journal of Clinical Microbiology.  44:709-715. 2006


    Year Title Altmetric
    2019 Preface.  Ed. 1870.  2019

    Education And Training

  • Doctor of Philosophy in Molecular Biology, Free University of Berlin 2009
  • Full Name

  • Romi Gupta